List of Tables
Table 1: Prostate Cancer Therapeutics, Commonly Mutated or Overexpressed Genes 12
Table 2: Prostate Cancer Therapeutics, Disease Stage Classification 15
Table 3: Prostate Cancer Therapeutics, Risk Classification for Localized Cancer, D’Amico System 16
Table 4: Prostate Cancer Therapeutics, Common Definitions of High-Risk Prostate Cancer 16
Table 5: Marketed GnRH Agonists and Their Routes of Administration for Prostate Cancer 21
Table 6: Prostate Cancer Therapeutics, Top Five European Markets, Forecast Growth in Prevalence and Treatment Populations, 2014–2021 91
Table 7: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014–2021 93
Table 8: Prostate Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2014–2021 95
Table 9: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Discovery, 2015 112
Table 10: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Preclinical, 2015 116
Table 11: Prostate Cancer Therapeutics, Global, Developmental Pipeline, IND/CTA-Filed, 2015 131
Table 12: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2015 131
Table 13: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2015 137
Table 14: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2015 145
Table 15: Prostate Cancer Market, Global, Market Forecasts, 2014–2021 146
Table 16: Prostate Cancer Market, US, Market Forecasts, 2014–2021 146
Table 17: Prostate Cancer Market, Canada, Market Forecasts, 2014–2021 146
Table 18: Prostate Cancer Market, The UK, Market Forecasts, 2014–2021 147
Table 19: Prostate Cancer Market, France, Market Forecasts, 2014–2021 147
Table 20: Prostate Cancer Market, Germany, Market Forecasts, 2014–2021 147
Table 21: Prostate Cancer Market, Italy, Market Forecasts, 2014–2021 148
Table 22: Prostate Cancer Market, Spain, Market Forecasts, 2014–2021 148
Table 23: Prostate Cancer Market, Japan, Market Forecasts, 2014–2021 148